| NO | Behavior of Neoplasm | 코드 | 조직학적 진단명 | 2017년 | 2016년 | 전년대비 | |||
|---|---|---|---|---|---|---|---|---|---|
| 환자수 | 구성비 | 환자수 | 구성비 | 증감수 | 증감율 | ||||
| 1 | Benign (양성암) |
M82720 | Pituitary adenoma, NOS(C75.1) | 12 | 0.65% | 9 | 0.52% | 3 | 33.3% |
| M91200 | Hemangioma, NOS | - | 0.00% | 1 | 0.06% | -1 | -100% | ||
| M91210 | Cavernous hemangioma | 3 | 0.16% | - | 0.00% | 3 | |||
| M93900 | Choroid plexus papilloma, NOS(C71.5) | 1 | 0.05% | - | 0.00% | 1 | |||
| M95300 | Meningioma, NOS | 6 | 0.32% | 4 | 0.23% | 2 | 50.0% | ||
| M95310 | Meningothelial meningioma | 2 | 0.11% | - | 0.00% | 2 | |||
| M95320 | Fibrous meningioma | - | 0.00% | 1 | 0.06% | -1 | -100% | ||
| M95370 | Transitional meningioma | 2 | 0.11% | 2 | 0.11% | 0 | 0.0% | ||
| M95600 | Neurilemmoma | 5 | 0.27% | 3 | 0.17% | 2 | 66.7% | ||
| Benign 합계 | 31 | 1.68% | 20 | 1.14% | 11 | 55.0% | |||
| 2 | Uncertain whether benign or malignant (양성 또는 악성여부 불확실) |
M80001 | Neoplasm, uncertain whether benign or malignant | 6 | 0.32% | 3 | 0.17% | 3 | 100% |
| M91611 | Hemangioblastoma | 2 | 0.11% | 1 | 0.06% | 1 | 100% | ||
| M93501 | Craniopharyngioma(C75.2) | 1 | 0.05% | - | 0.00% | 1 | |||
| M94211 | Pilocytic astrocytoma(C71._) | 1 | 0.05% | - | 0.00% | 1 | |||
| M95061 | Central neurocytoma | 1 | 0.05% | - | 0.00% | 1 | |||
| Uncertain whether benign or malignant 합계 | 11 | 0.60% | 4 | 0.23% | 7 | 175% | |||
| 3 | Carcinoma in situ (정상소재암) |
M80102 | Carcinoma in situ, NOS | 5 | 0.27% | 6 | 0.34% | -1 | -16.7% |
| M80702 | Squamous cell carcinoma in situ, NOS | 6 | 0.32% | 9 | 0.52% | -3 | -33.3% | ||
| M80772 | CIN III with severe dysplasia(C53._) | 16 | 0.87% | 16 | 0.92% | 0 | 0.0% | ||
| M80812 | Bowen disease(C44._) | 2 | 0.11% | 2 | 0.11% | 0 | 0.0% | ||
| M81202 | Transitional cell carcinoma in situ | 9 | 0.49% | 3 | 0.17% | 6 | 200% | ||
| M81302 | Papillary transitional cell carcinoma, non-invasive(C67._) | 15 | 0.81% | 23 | 1.32% | -8 | -34.8% | ||
| M81402 | Adenocarcinoma in situ, NOS | 3 | 0.16% | 8 | 0.46% | -5 | -62.5% | ||
| M82012 | Ductal carcinoma in situ, cribriform type(C50._) | 2 | 0.11% | 1 | 0.06% | 1 | 100% | ||
| M82102 | Adenocarcinoma in situ in tubular adenoma | 6 | 0.32% | 1 | 0.06% | 5 | 500% | ||
| M82112 | Tubular adenocarcinoma in situ | 7 | 0.38% | 1 | 0.06% | 6 | 600% | ||
| M82302 | Ductal carcinoma in situ, solid type(C50._) | 2 | 0.11% | 1 | 0.06% | 1 | 100% | ||
| M82612 | Adenocarcinoma in situ in villous adenoma | - | 0.00% | 1 | 0.06% | -1 | -100% | ||
| M82632 | Adenocarcinoma in situ in tubulovillous adenoma | 2 | 0.11% | 2 | 0.11% | 0 | 0.0% | ||
| M84532 | Intraductal papillary-mucinous carcinoma, non-invasive(C25._) | 1 | 0.05% | - | 0.00% | 1 | |||
| M85002 | Ductal carcinoma in situ, NOS(C50._) | 4 | 0.22% | 2 | 0.11% | 2 | 100% | ||
| M85012 | Ductal carcinoma in situ, comedo type(C50._) | 2 | 0.11% | 1 | 0.06% | 1 | 100% | ||
| M85032 | Intraductal papillary neoplasm with high grade intraepithelial neoplasia | 2 | 0.11% | 3 | 0.17% | -1 | -33.3% | ||
| M85072 | Intraductal micropapillary carcinoma(C50._) | - | 0.00% | 2 | 0.11% | -2 | -100% | ||
| M85202 | Lobular carcinoma in situ, NOS(C50._) | - | 0.00% | 2 | 0.11% | -2 | -100% | ||
| Carcinoma in situ 합계 | 84 | 4.55% | 84 | 4.81% | 0 | 0.0% | |||
| 4 | Malignant, primary site (악성, 원발부위암) |
M80003 | Malignant neoplasm, NOS | 250 | 13.54% | 291 | 16.66% | -41 | -14.1% |
| M80103 | Carcinoma, NOS | 14 | 0.76% | 15 | 0.86% | -1 | -6.7% | ||
| M80133 | Large cell neuroendocrine carcinoma | 4 | 0.22% | 2 | 0.11% | 2 | 100% | ||
| M80203 | Carcinoma, undifferentiated, NOS | 2 | 0.11% | 2 | 0.11% | 0 | 0.0% | ||
| M80213 | Carcinoma, anaplastic, NOS | 1 | 0.05% | - | 0.00% | 1 | |||
| M80333 | Pseudosarcomatous carcinoma | 5 | 0.27% | 2 | 0.11% | 3 | 150% | ||
| M80413 | Small cell carcinoma, NOS | 25 | 1.35% | 12 | 0.69% | 13 | 108.3% | ||
| M80463 | Non-small cell carcinoma(C34._) | 9 | 0.49% | 15 | 0.86% | -6 | -40.0% | ||
| M80503 | Papillary carcinoma, NOS | 1 | 0.05% | - | 0.00% | 1 | |||
| M80703 | Squamous cell carcinoma, NOS | 94 | 5.09% | 95 | 5.44% | -1 | -1.1% | ||
| M80713 | Squamous cell carcinoma, keratinizing, NOS | 13 | 0.70% | 8 | 0.46% | 5 | 62.5% | ||
| M80723 | Squamous cell carcinnoma, large cell, nonkeratinizing, NOS | 15 | 0.81% | 10 | 0.57% | 5 | 50.0% | ||
| M80763 | Squamous cell carcinoma, microinvasive | 1 | 0.05% | 2 | 0.11% | -1 | -50.0% | ||
| M80833 | Basaloid squamous cell carcinoma | 1 | 0.05% | 1 | 0.06% | 0 | 0.0% | ||
| M80903 | Basal cell carcinoma, NOS(C44._) | 4 | 0.22% | 6 | 0.34% | -2 | -33.3% | ||
| M81203 | Transitional cell carcinoma, NOS | 37 | 2.00% | 37 | 2.12% | 0 | 0.0% | ||
| M81303 | Papillary transitional cell carcinoma (C67._) | 14 | 0.76% | 19 | 1.09% | -5 | -26.3% | ||
| M81403 | Adenocarcinoma, NOS | 357 | 19.33% | 328 | 18.78% | 29 | 8.8% | ||
| M81443 | Adenocarcinoma, intestinal type(C16._) | - | 0.00% | 1 | 0.06% | -1 | -100% | ||
| M81603 | Cholangiocarcinoma(C22.1, C24.0) | 43 | 2.33% | 46 | 2.63% | -3 | -6.5% | ||
| M81623 | Klatskin tumor(C22.1, C24.0) | 12 | 0.65% | 13 | 0.74% | -1 | -7.7% | ||
| M81633 | Pancreatobiliary type adenocarcinoma | 2 | 0.11% | - | 0.00% | 2 | |||
| M81703 | Hepatocellular carcinoma, NOS(C22.0) | 103 | 5.58% | 103 | 5.90% | 0 | 0.0% | ||
| M81743 | Hepatocellular carcinoma, clear cell type(C22.0) | - | 0.00% | 1 | 0.06% | -1 | -100% | ||
| M81803 | Combined hepatocellular carcinoma and cholangiocarcinoma | 2 | 0.11% | - | 0.00% | 2 | |||
| M82003 | Adenoid cystic carcinoma | 1 | 0.05% | 3 | 0.17% | -2 | -66.7% | ||
| M82013 | Cribriform carcinoma, NOS | - | 0.00% | 1 | 0.06% | -1 | -100% | ||
| M82103 | Adenocarcinoma in tubular adenoma | 10 | 0.54% | 9 | 0.52% | 1 | 11.1% | ||
| M82113 | Tubular adenocarcinoma | 80 | 4.33% | 78 | 4.46% | 2 | 2.6% | ||
| M82303 | Solid carcinoma, NOS | 5 | 0.27% | 2 | 0.11% | 3 | 150% | ||
| M82403 | Neuroendocrine tumor, grade 1 | 3 | 0.16% | 7 | 0.40% | -4 | -57.1% | ||
| M82463 | Neuroendocrine carcinoma, NOS | 1 | 0.05% | 8 | 0.46% | -7 | -87.5% | ||
| M82473 | Merkel cell carcinoma(C44._) | - | 0.00% | 1 | 0.06% | -1 | -100% | ||
| M82493 | Neuroendocrine tumor, grade 2 | 2 | 0.11% | 2 | 0.11% | 0 | 0.0% | ||
| M82603 | Papillary adenocarcinoma, NOS | 122 | 6.61% | 116 | 6.64% | 6 | 5.2% | ||
| M82613 | Adenocarcinoma in villous adenoma | 1 | 0.05% | - | 0.00% | 1 | |||
| M82623 | Villous adenocarcinoma | 1 | 0.05% | - | 0.00% | 1 | |||
| M82633 | Adenocarcinoma in tubulovillous adenoma | 8 | 0.43% | 10 | 0.57% | -2 | -20.0% | ||
| M83103 | Clear cell adenocarcinoma, NOS | 4 | 0.22% | 1 | 0.06% | 3 | 300% | ||
| M83123 | Renal cell carcinoma, NOS(C64.9) | 36 | 1.95% | 37 | 2.12% | -1 | -2.7% | ||
| M83173 | Renal cell carcinoma, chromophobe type(C64.9) | 3 | 0.16% | 1 | 0.06% | 2 | 200% | ||
| M83183 | Renal cell carcinoma, sarcomatoid(C64.9) | 1 | 0.05% | - | 0.00% | 1 | |||
| M83303 | Follicular adenocarcinoma, NOS(C73.9) | 3 | 0.16% | 2 | 0.11% | 1 | 50.0% | ||
| M83353 | Follicular carcinoma, minimally, invasive(C73.9) | 1 | 0.05% | - | 0.00% | 1 | |||
| M83403 | Papillary carcinoma, follicular variant(C73.9) | 7 | 0.38% | 5 | 0.29% | 2 | 40.0% | ||
| M83803 | Endometrioid carcinoma, NOS | 17 | 0.92% | 6 | 0.34% | 11 | 183.3% | ||
| M83843 | Adenocarcinoma, endocervical type | 1 | 0.05% | - | 0.00% | 1 | |||
| M84103 | Sebaceous carcinoma(C44._) | - | 0.00% | 1 | 0.06% | -1 | -100% | ||
| M84303 | Mucoepidermoid carcinoma | 2 | 0.11% | 2 | 0.11% | 0 | 0.0% | ||
| M84413 | Serous adenocarcinoma, NOS | 8 | 0.43% | 7 | 0.40% | 1 | 14.3% | ||
| M84533 | Intraductal papillary-mucinous carcinoma, invasive(C25._) | 2 | 0.11% | - | 0.00% | 2 | |||
| M84703 | Mucinous cystadenocarcinoma, NOS(C56.9) | 2 | 0.11% | - | 0.00% | 2 | |||
| M84803 | Mucinous adenocarcinoma | 18 | 0.97% | 11 | 0.63% | 7 | 63.6% | ||
| M84903 | Signet ring cell carcinoma | 19 | 1.03% | 22 | 1.26% | -3 | -13.6% | ||
| M85003 | Infiltrating duct carcinoma, NOS(C50._) | 69 | 3.74% | 73 | 4.18% | -4 | -5.5% | ||
| M85033 | Intraductal papillary adenocarcinoma with invasion(C50._) | 4 | 0.22% | - | 0.00% | 4 | |||
| M85103 | Medullary carcinoma, NOS | 1 | 0.05% | - | 0.00% | 1 | |||
| M85123 | Medullary carcinoma with lymphoid stroma | - | 0.00% | 1 | 0.06% | -1 | -100% | ||
| M85203 | Lobular carcinoma, NOS(C50._) | 8 | 0.43% | 5 | 0.29% | 3 | 60.0% | ||
| M85223 | Infiltrating duct and lobular carcinoma, NOS(C50._) | 1 | 0.05% | - | 0.00% | 1 | |||
| M85233 | Infiltrating duct and tubular carcinoma(C50._) | - | 0.00% | 2 | 0.11% | -2 | -100% | ||
| M85423 | Paget disease, extramammary (for all sites except breast) | 3 | 0.16% | 1 | 0.06% | 2 | 200% | ||
| M85433 | Paget disease and intraductal carcinoma of breast(C50._) | 1 | 0.05% | - | 0.00% | 1 | |||
| M85503 | Acinar cell carcinoma | 98 | 5.31% | 54 | 3.09% | 44 | 81.5% | ||
| M85603 | Adenosquamous carcinoma | 3 | 0.16% | 5 | 0.29% | -2 | -40.0% | ||
| M85733 | Adenocarcinoma with apocrine metaplasia | 1 | 0.05% | - | 0.00% | 1 | |||
| M85803 | Thymoma, malignant, NOS(C37.9) | - | 0.00% | 2 | 0.11% | -2 | -100% | ||
| M85823 | Thymoma type AB, malignant(C37.9) | 2 | 0.11% | 1 | 0.06% | 1 | 100% | ||
| M85833 | Thymoma, type B1, malignant(C37.9) | 2 | 0.11% | 1 | 0.06% | 1 | 100% | ||
| M85843 | Thymoma, type B2, malignant(C37.9) | 1 | 0.05% | - | 0.00% | 1 | |||
| M85853 | Thymoma, type B3, malignant(C37.9) | 1 | 0.05% | 1 | 0.06% | 0 | 0.0% | ||
| M85863 | Thymic carcinoma, NOS(C37.9) | 1 | 0.05% | - | 0.00% | 1 | |||
| M86203 | Granulosa cell carcinoma(C56.9) | - | 0.00% | 1 | 0.06% | -1 | -100% | ||
| M87203 | Malignant melanoma, NOS (except jubenile melanoma M-8770/0) | 4 | 0.22% | 5 | 0.29% | -1 | -20.0% | ||
| M87213 | Nodular melanoma(C44._) | - | 0.00% | 2 | 0.11% | -2 | -100% | ||
| M88003 | Sarcoma, NOS | 2 | 0.11% | 3 | 0.17% | -1 | -33.3% | ||
| M88013 | Spindle cell carcinoma | 1 | 0.05% | - | 0.00% | 1 | |||
| M88033 | Small cell sarcoma | 1 | 0.05% | 1 | 0.06% | 0 | 0.0% | ||
| M88053 | Undifferentiated sarcoma | - | 0.00% | 1 | 0.06% | -1 | -100% | ||
| M88113 | Fibromyxosarcoma | - | 0.00% | 1 | 0.06% | -1 | -100% | ||
| M88303 | Malignant fibrous histiocytoma | - | 0.00% | 1 | 0.06% | -1 | -100% | ||
| M88323 | Dermatofibrosarcoma, NOS(C44._) | 2 | 0.11% | 1 | 0.06% | 1 | 100% | ||
| M88513 | Liposarcoma, well differentiated | 1 | 0.05% | 2 | 0.11% | -1 | -50.0% | ||
| M88583 | Dedifferentiated liposarcoma | - | 0.00% | 2 | 0.11% | -2 | -100% | ||
| M88903 | Leiomyosarcoma, NOS | 1 | 0.05% | - | 0.00% | 1 | |||
| M89303 | Endometrial stromal sarcoma, NOS(C54.1) | 2 | 0.11% | - | 0.00% | 2 | |||
| M89363 | Gastrointestinal stromal sarcoma | 11 | 0.60% | 13 | 0.74% | -2 | -15.4% | ||
| M89413 | Carcinoma in pleomorphic adenoma | 1 | 0.05% | - | 0.00% | 1 | |||
| M89503 | Mullerian mixed tumor | 1 | 0.05% | - | 0.00% | 1 | |||
| M89803 | Carcinosarcoma, NOS | 4 | 0.22% | - | 0.00% | 4 | |||
| M90503 | Mesothelioma, malignant | 3 | 0.16% | 2 | 0.11% | 1 | 50.0% | ||
| M90613 | Seminoma, NOS(C62._) | - | 0.00% | 1 | 0.06% | -1 | -100% | ||
| M90643 | Germinoma | 1 | 0.05% | - | 0.00% | 1 | |||
| M91203 | Hemangiosarcoma | 4 | 0.22% | 3 | 0.17% | 1 | 33.3% | ||
| M91503 | Hemangiopericytoma, malignant | - | 0.00% | 1 | 0.06% | -1 | -100% | ||
| M91803 | Osteosarcoma, NOS(C40._, C41._) | - | 0.00% | 1 | 0.06% | -1 | -100% | ||
| M92203 | Chondrosarcoma, NOS(C40._, C41_) | 1 | 0.05% | - | 0.00% | 1 | |||
| M92603 | Ewing sarcoma | - | 0.00% | 1 | 0.06% | -1 | -100% | ||
| M93623 | Pineoblastoma(C75.3) | 2 | 0.11% | - | 0.00% | 2 | |||
| M93643 | Neuroectodermal tumor, NOS | - | 0.00% | 1 | 0.06% | -1 | -100% | ||
| M93803 | Glioma, malignant(C71._) | 2 | 0.11% | - | 0.00% | 2 | |||
| M93913 | Ependymoma, NOS(C71._) | 1 | 0.05% | - | 0.00% | 1 | |||
| M93923 | Ependymoma, anaplastic(C71._) | - | 0.00% | 1 | 0.06% | -1 | -100% | ||
| M94003 | Astrocytoma, NOS(C71._) | - | 0.00% | 2 | 0.11% | -2 | -100% | ||
| M94013 | Astrocytoma, anaplastic(C71._) | - | 0.00% | 1 | 0.06% | -1 | -100% | ||
| M94403 | Glioblastoma, NOS(C71._) | 8 | 0.43% | 11 | 0.63% | -3 | -27.3% | ||
| M94423 | Polar spongioblastoma(C71._) | 1 | 0.05% | - | 0.00% | 1 | |||
| M94513 | Oligodendroglioma, anaplastic(C71._) | - | 0.00% | 1 | 0.06% | -1 | -100% | ||
| M94703 | Medulloblastoma, NOS(C71.6) | - | 0.00% | 1 | 0.06% | -1 | -100% | ||
| M94723 | Medullomyoblastoma(C71.6) | - | 0.00% | 1 | 0.06% | -1 | -100% | ||
| M95303 | Meningioma, anaplastic | - | 0.00% | 1 | 0.06% | -1 | -100% | ||
| M95403 | Malignant peripheral nerve sheath tumor | 1 | 0.05% | 1 | 0.06% | 0 | 0.0% | ||
| M95903 | Malignant lymphoma, NOS | 3 | 0.16% | 5 | 0.29% | -2 | -40.0% | ||
| M95913 | B cell lymphoma, NOS | - | 0.00% | 1 | 0.06% | -1 | -100% | ||
| M96503 | Hodgkin lymphoma, NOS | - | 0.00% | 2 | 0.11% | -2 | -100% | ||
| M96523 | Hodgkin lymphoma, mixed cellularity, NOS | 1 | 0.05% | 2 | 0.11% | -1 | -50.0% | ||
| M96633 | Hodgkin lymphoma, nodular sclerosis, NOS | 2 | 0.11% | - | 0.00% | 2 | |||
| M96733 | Mantle cell lymphoma(includes all variant: blastic, pleomorphic, small cell) | - | 0.00% | 1 | 0.06% | -1 | -100% | ||
| M96793 | Mediastinal large B-cell lymphoma(C38.3) | 1 | 0.05% | 1 | 0.06% | 0 | 0.0% | ||
| M96803 | Malignant lymphoma, large B-cell, diffuse, NOS | 22 | 1.19% | 19 | 1.09% | 3 | 15.8% | ||
| M96873 | Burkitt lymphoma, NOS | 1 | 0.05% | 1 | 0.06% | 0 | 0.0% | ||
| M96903 | Follicular lymphoma, NOS | 1 | 0.05% | - | 0.00% | 1 | |||
| M96913 | Follicular lymphoma, grade 2 | 1 | 0.05% | 1 | 0.06% | 0 | 0.0% | ||
| M96983 | Folloicular lymphoma, grade 3 | - | 0.00% | 2 | 0.11% | -2 | -100% | ||
| M96993 | Marginal zone B-cell lymphoma, NOS | 5 | 0.27% | 1 | 0.06% | 4 | 400% | ||
| M97023 | Mature T-cell lymphoma, NOS | 4 | 0.22% | 4 | 0.23% | 0 | 0.0% | ||
| M97053 | Angioimmunoblastic T-cell lymphoma | - | 0.00% | 2 | 0.11% | -2 | -100% | ||
| M97193 | NK/T-cell lymphoma, nasal and nasal-type | 1 | 0.05% | 1 | 0.06% | 0 | 0.0% | ||
| M97253 | Hydroa vacciniforme-like lymphoma | - | 0.00% | 1 | 0.06% | -1 | -100% | ||
| M97313 | Plasmacytoma, NOS | - | 0.00% | 5 | 0.29% | -5 | -100% | ||
| M97323 | Multiple myeloma(C42.1) | 14 | 0.76% | 13 | 0.74% | 1 | 7.7% | ||
| M97513 | Langerhans cell histiocytosis, NOS | 1 | 0.05% | - | 0.00% | 1 | |||
| M97613 | Waldenstrom macroglobulinemia(C42.0) | 1 | 0.05% | - | 0.00% | 1 | |||
| M98003 | Leukemia, NOS | 2 | 0.11% | 3 | 0.17% | -1 | -33.3% | ||
| M98013 | Acute leukemia, NOS | 1 | 0.05% | 2 | 0.11% | -1 | -50.0% | ||
| M98313 | T-cell large granular lymphocytic leukemia | 1 | 0.05% | - | 0.00% | 1 | |||
| M98353 | Precursor cell lymphoblastic leukemia, NOS | 1 | 0.05% | - | 0.00% | 1 | |||
| M98373 | Precursor T-cell lymphoblastic leukemia | 1 | 0.05% | - | 0.00% | 1 | |||
| M98613 | Acute myeloid leukemia, NOS | 9 | 0.49% | 3 | 0.17% | 6 | 200% | ||
| M98633 | Chronic myeloid leukemia, NOS | 4 | 0.22% | 2 | 0.11% | 2 | 100% | ||
| M98663 | Acute promyelocytic leukemia (t15;17)(q22;q11-12) | 1 | 0.05% | - | 0.00% | 1 | |||
| M98723 | Acute myeloblastic leukemia | 1 | 0.05% | 1 | 0.06% | 0 | 0.0% | ||
| M99303 | Myeloid sarcoma | - | 0.00% | 1 | 0.06% | -1 | -100% | ||
| M99403 | Hairy cell leukemia variant | - | 0.00% | 1 | 0.06% | -1 | -100% | ||
| M99453 | Chronic myelomonocytic leukemia, NOS | - | 0.00% | 1 | 0.06% | -1 | -100% | ||
| M99503 | Polycythemia vera | 1 | 0.05% | 2 | 0.11% | -1 | -50.0% | ||
| M99603 | Chronic myeloproliferative disease, NOS | 3 | 0.16% | - | 0.00% | 3 | |||
| M99613 | Primary myelofibrosis | 1 | 0.05% | - | 0.00% | 1 | |||
| M99623 | Essential thrombocythemia | 4 | 0.22% | 2 | 0.11% | 2 | 100% | ||
| M99803 | Refractory anemia | - | 0.00% | 1 | 0.06% | -1 | -100% | ||
| M99833 | Refractory anemia with excess of blasts | - | 0.00% | 1 | 0.06% | -1 | -100% | ||
| M99853 | Refractory cytopenia with multilineage dysplasia | 1 | 0.05% | 2 | 0.11% | -1 | -50.0% | ||
| M99893 | Myelodysplastic syndrome, NOS | 14 | 0.76% | 5 | 0.29% | 9 | 180% | ||
| Malignant, primary site 합계 | 1,721 | 93.18% | 1,639 | 93.82% | 82 | 5.0% | |||
| 합 계 | 1,847 | 100% | 1,747 | 100% | 100 | 5.7% | |||